drugset
drugset / Trial / NCT00445679

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD

NCT00445679 ↗

Phase 3 Completed 807 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.

Timeline

Start
2007-07
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 50 mg —
Subject Desvenlafaxine Other / unclassified 100 mg —
Subject Desvenlafaxine Other / unclassified 200 mg —
Comparator Paroxetine Small molecule 20 mg —

Indications

major depressive disorder